BioStock: Alligator Bioscience strengthens its position after an eventful autumn 2025
Alligator Bioscience enters the end of 2025 with renewed momentum. The autumn has been marked by strengthened scientific validation, important clinical data readouts and decisive financial measures aimed at supporting the company’s continued journey toward phase III readiness for its flagship candidate mitazalimab. BioStock contacted CEO Søren Bregenholt and CFO Johan Giléus for an update on the company’s progress and priorities.
Read the article at biostock.se:
Alligator Bioscience strengthens its position after an eventful autumn 2025
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/